Palisade Bio Statistics
Share Statistics
Palisade Bio has 1.43M shares outstanding. The number of shares has increased by -87.15% in one year.
| Shares Outstanding | 1.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 26.49% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.40M |
| Failed to Deliver (FTD) Shares | 2.48K |
| FTD / Avg. Volume | 0.21% |
Short Selling Information
The latest short interest is 43.11K, so 3.24% of the outstanding shares have been sold short.
| Short Interest | 43.11K |
| Short % of Shares Out | 3.24% |
| Short % of Float | 3.3% |
| Short Ratio (days to cover) | 0.29 |
Valuation Ratios
The PE ratio is -0.33 and the forward PE ratio is -0.26.
| PE Ratio | -0.33 |
| Forward PE | -0.26 |
| PS Ratio | 16.14 |
| Forward PS | 0.2 |
| PB Ratio | 0.36 |
| P/FCF Ratio | -0.36 |
| PEG Ratio | n/a |
Enterprise Valuation
Palisade Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.15 |
| Quick Ratio | 5.15 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.38 |
| Cash Flow / Debt | -70.46 |
| Interest Coverage | -871.33 |
Financial Efficiency
Return on equity (ROE) is -1.09% and return on capital (ROIC) is -111.88%.
| Return on Equity (ROE) | -1.09% |
| Return on Assets (ROA) | -0.88% |
| Return on Capital (ROIC) | -111.88% |
| Revenue Per Employee | 27.78K |
| Profits Per Employee | -1.37M |
| Employee Count | 9 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -79.37% in the last 52 weeks. The beta is 1.33, so Palisade Bio 's price volatility has been higher than the market average.
| Beta | 1.33 |
| 52-Week Price Change | -79.37% |
| 50-Day Moving Average | 2.77 |
| 200-Day Moving Average | 4.28 |
| Relative Strength Index (RSI) | 40.66 |
| Average Volume (20 Days) | 1.19M |
Income Statement
In the last 12 months, Palisade Bio had revenue of $250.00K and earned -$12.30M in profits. Earnings per share was $-27.01.
| Revenue | 250.00K |
| Gross Profit | 250.00K |
| Operating Income | -13.07M |
| Net Income | -12.30M |
| EBITDA | -12.28M |
| EBIT | -13.07M |
| Earnings Per Share (EPS) | -27.01 |
Balance Sheet
The company has $12.43M in cash and $369.00K in debt, giving a net cash position of $12.06M.
| Cash & Cash Equivalents | 12.43M |
| Total Debt | 369.00K |
| Net Cash | 12.06M |
| Retained Earnings | -121.51M |
| Total Assets | 9.34M |
| Working Capital | 6.19M |
Cash Flow
In the last 12 months, operating cash flow was -$11.13M and capital expenditures -$4.00K, giving a free cash flow of -$11.14M.
| Operating Cash Flow | -11.13M |
| Capital Expenditures | -4.00K |
| Free Cash Flow | -11.14M |
| FCF Per Share | -24.42 |
Margins
Gross margin is 100%, with operating and profit margins of -5.23K% and -4.92K%.
| Gross Margin | 100% |
| Operating Margin | -5.23K% |
| Pretax Margin | -4.92K% |
| Profit Margin | -4.92K% |
| EBITDA Margin | -4.91K% |
| EBIT Margin | -5.23K% |
| FCF Margin | -4.45K% |
Dividends & Yields
PALI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1525.99% |
| FCF Yield | -440.22% |
Analyst Forecast
The average price target for PALI is $23, which is 1199.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $23 |
| Price Target Difference | 1199.4% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Apr 8, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Apr 8, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -23.81 |
| Piotroski F-Score | 2 |